

IOptima raises \$7.2 million in Series B financing

Tel-Aviv, Israel, December 31st, 2015 – IOptima Ltd., a developer of minimally invasive surgical ophthalmic devices, announced today that it has secured a \$7.2M investment from its existing shareholders and two Asia-based venture capital firms via a private placement. The financing will help IOptima to continue the global commercialization of its innovative IOptimate™ system used in the treatment of glaucoma, as well as to initiate a regulatory approval pathway process for the IOptimate™ system with the U.S. Food and Drug Administration, commencing 2016.

IOptima's flagship product, IOptiMate®, is based on CO₂ laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball. The IOptiMate procedure (CLASS®) provides high efficacy and allows for substantial reductions in post-operative complications and use of eye drops compared with alternatives. Recent marketing efforts by IOptima have resulted in first sales of the IOptiMate in various markets in Europe and Asia.

"The company's first product is already generating revenues and the new money will help us to develop more products and promote the FDA regulatory approval in the US market. China is a very important market for us with a great potential, because we have already received a CFDA approval and began commercial operations and because our product and procedure is very suitable for Chinese eyes. It was important for me to bring onboard Chinese investors specializing in the medical field to help us penetrate the Chinese market effectively and take advantage of the opportunities that exist in it for us" said Ronen Castro, CEO of IOptima.

"IOptima is a company with excellent products and an experienced and professional team with clear operative plans for the coming years. The fact that the company has already received the regulatory approval in China and the positive feedback we received from local glaucoma specialists, certainly helped our decision to invest in the company. This is just the beginning for us and we certainly see great potential for the future. Our goal to assist the company as investors who specialize in the medical field to achieve its goals" said Mr. Liu Bo, Investment Director at Infinity Beijing, the leading investor in IOptima.

ABOUT IOptima, Ltd.

Founded in 2005, IOptima Ltd. develops, manufactures, and sells novel laser-based surgical devices for the minimally invasive treatment of glaucoma. With a mission to address the unmet needs and common safety problems in glaucoma surgery, the company developed its flagship product, the IOptimate®, a state-of-the-art surgical system. The procedure, CO₂ Laser-Assisted Sclerectomy Surgery (CLASS), provides long-term relief from elevated intraocular pressure while reducing or omitting the reliance on glaucoma drugs. IOptima is part of the BIOLIGHT group, www.bio-light.co.il. For more information, visit <http://www.ioptima.co.il>.



Media Contact: Liron Rosenbaum
liron@ioptima.co.il
+972.73.2753428